Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muro K, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–26.

Article  CAS  PubMed  Google Scholar 

Frenel JS, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–41.

Article  CAS  PubMed  Google Scholar 

Marabelle A, et al. Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.

Article  CAS  PubMed  Google Scholar 

Le DT, et al. Phase II open-label study of Pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9.

Article  CAS  PubMed  Google Scholar 

Johnson DB, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–67.

Article  PubMed  PubMed Central  Google Scholar 

Heinzerling L, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.

Article  PubMed  PubMed Central  Google Scholar 

Patel RP, et al. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep. 2021;23(7):79.

Article  PubMed  PubMed Central  Google Scholar 

Naqash AR, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the national cancer institute-cancer therapy evaluation program. J Clin Oncol. 2022;40(29):3439–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahmood SS, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palassin P, et al. Underreporting of major cardiac adverse events with immune checkpoint inhibitors in clinical trials: importance of postmarketing pharmacovigilance surveys. J Clin Oncol. 2023;41(5):1154–6.

Article  PubMed  Google Scholar 

Wu S, et al. Cardiovascular adverse events induced by immune checkpoint inhibitors: a real world study from 2018 to 2022. Front Cardiovasc Med. 2022;9:969942.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Bhatti SA, Ying J. Immune checkpoint inhibitors-associated cardiotoxicity. Cancers. 2022;14(5):1145.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alemohammad H, et al. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacother. 2022;146:112516.

Article  CAS  PubMed  Google Scholar 

Khan M, Arooj S, Wang H. Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy. Front Immunol. 2021;12:651634.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alizadeh M, et al. The potentials of immune checkpoints for the treatment of blood malignancies. Crit Rev Oncol Hematol. 2020;153:103031.

Article  PubMed  Google Scholar 

Tang S, et al. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86:106700.

Article  CAS  PubMed  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang DY, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8.

Article  PubMed  PubMed Central  Google Scholar 

Raschi E, et al. Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians. Drug Saf. 2023;46(9):819–33.

Article  PubMed  PubMed Central  Google Scholar 

Ronen D, et al. Exploring the mechanisms underlying the cardiotoxic effects of immune checkpoint inhibitor therapies. Vaccines. 2022;10(4):540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haanen J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–38.

Article  CAS  PubMed  Google Scholar 

Rubio-Infante N, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23(10):1739–47.

Article  CAS  PubMed  Google Scholar 

Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology. 2019;58(Suppl 7):vii59–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baik AH, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128(11):1780–801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson DB, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.

Article  PubMed  PubMed Central  Google Scholar 

Martinez-Calle N, et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica. 2018;103(7):e318–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waterhouse P, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985–8.

Article  CAS  PubMed  Google Scholar 

Ying H, et al. Cutting edge: CTLA-4–B7 interaction suppresses Th17 cell differentiation. J Immunol. 2010;185(3):1375–8.

Article  CAS  PubMed  Google Scholar 

Tivol EA, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7.

Article  CAS  PubMed  Google Scholar 

Kreidieh F, McQuade J. Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: beyond ischemia with non-obstructive coronary arteries (INOCA). Am Heart J Plus. 2024;40:100374.

PubMed  PubMed Central